[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated December 3, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

920 Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma

Oral and Poster Abstracts
Oral Session: Lymphoma: Chemotherapy, excluding Pre-Clinical Models - New Treatments
Tuesday, December 8, 2009: 7:45 AM
260-262 (Ernest N. Morial Convention Center)

Brad Pohlman1, Ranjana Advani, MD2, Madeleine Duvic, MD3, Kenneth B. Hymes, MD4, Tanin Intragumtornchai, MD5, Arnuparp Lekhakula6*, Ofer Shpilberg7*, Adam Lerner, MD8, Dina Ben-Yehuda9, Marie beylot-Barry10*, Uwe Hillen11*, Jan Fagerberg12* and Francine M Foss13

1Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
2Stanford University, Stanford, CA
3M.D. Anderson Cancer Center, Houston, TX
4New York Univ. Cancer Institute, New York, NY
5Dept. of Medicine, Chulalongkorn Hospital, Bangkok, Thailand
6Department of Medicine, Songlanagarind Hospital, Songkhla, Thailand
7Hematology, Rabin Medical Center, Beilinson Hospital, Davidoff Cancer Center and Sackler School of Medicine, Tel Aviv University, Petach Tikva, Israel
8Boston Medical Center, Boston, MA
9Division of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
10Hopital du Haut-Leveque, Pessac, France
11Universitatsklinikum Essen, Essen, Germany
12TopoTarget, Copenhagen, Denmark
13Yale Cancer Center, New Haven, CT

Background: Belinostat is a pan-HDAC inhibitor of the hydroxamate chemical class that is well-tolerated and has shown clinical activity.

 

Methods: Open label, multicenter trial enrolling patients (pts) with peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL) who failed ≥ 1 prior systemic therapy. Pts received 1000 mg/m2 IV belinostat over 30 min on days 1 to 5 of a 3-wk cycle. Primary endpoint was objective response (OR) assessed by IWG criteria for PTCL and by SWAT (cutaneous lesions) and IWG criteria (non-cutaneous lesions) for CTCL. Pruritus in pts with CTCL was assessed using a 10-point scale; relief defined as reduction of pruritus score of ≥ 3 points in pts with baseline score ≥ 3. ECGs were monitored and reviewed centrally (pre-/ post-infusion ECGs on all treatment days in cycle 1, and pre-/ post-infusion ECGs on day 1 of subsequent cycles) to evaluate potential cardiac toxicity.

 

 

Results: The study enrolled a total of 53 treated pts, including 20 and 29 evaluable pts with a diagnosis of PTCL and CTCL, respectively. The 20 pts with PTCL [10 PTCL-unspecified (PTCL-U), 3 anaplastic large cell lymphoma (ALCL), 3 angioimmunoblastic TCL (AITL), 3 NK/T-cell lymphoma, and 1 subcutaneous panniculitis-like TCL (SPTCL)] had received a median of 3 prior systemic therapies (range 1 – 10), and 40 % of them had stage IV disease. 5/20 (25%) PTCL pts responded with 2 CR (both in patients with PTCL-U) and 3 PR (PTCL-U, AITL, ALCL). The 5 responding pts had a median duration of response of 159+ days (range 1 – 504+). Additionally, SD was observed in 5 pts (2 PTCL-U, 2 NK/T-cell, and 1 ALCL) with median duration of SD of 109+ days (range 80 -185+).

 

The 29 pts with CTCL [15 mycosis fungoides (MF), 7 Sezary syndrome (SS), 5 non MF/SS, 2 unclassified] had received a median of 1 prior skin directed therapies (range 0 – 4) and 3 prior systemic therapies (range 1 – 9), and 55 % of them had stage IV disease. 4/29 (14%) CTCL pts responded with 2 CR (ALCL, MF) and 2 PR (MF, SS).  The 4 responding pts had a median duration of response of 273 days (range 48 - 469+). Importantly, time to response was short with a median of 16 days (range 14-35). In addition, SD was observed in 17 pts (10 MF, 3 SS, 2 non MF/SS, 2 unclassified) with current duration of up to 127 days. Pruritus relief (score reduction ≥ 3) was seen in 7 of 14 pts with significant baseline pruritis. Median time to pruritus relief was also short, 16 days (range 7-45).

 

Hematological toxicity was minimal without any grade 4 events (shift from baseline) and only one pt each experiencing grade 3 neutropenia and grade 3 thrombocytopenia, respectively. No grade 3 QTcF prolongation was detected in more than 700 ECGs.  Four grade 3/4 drug-related AEs were reported:  pruritis, rash/erythema, edema, and adynamic ileus.

 

Conclusions: Belinostat monotherapy is safe, well tolerated, and efficacious in pts with recurrent/refractory T-cell lymphoma with durable remissions in both CTCL and PTCL. These results are the basis for a pivotal study with belinostat monotherapy in pts with PTCL.

Disclosures: Advani: Seattle Genetics, Inc.: Research Funding. Duvic: Topotarget: research support for conduct of clinical trial. Fagerberg: TopoTarget A/S: Employment, Equity Ownership. Foss: Eisai : Speakers Bureau.

*signifies non-member of ASH